Cell and gene therapy

In recent years, advances within the cell and gene therapy sector have created incredible excitement about how these potentially curative treatments can transform the health of individuals and society as a whole.

However, complexities within the lifecycle of the delivery model—from the patient, to the manufacturing process, and back to the patient—require pharmaceutical and biotechnology companies to address significant and unique challenges associated with Cell and Gene Therapy development.
 
In this paper, we explore how organizations entering the Cell and Gene Therapy sector must transform their business to support the development of the therapy itself and deliver it in a human-centric way.